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In normal ovarian function a controlled angiogenesis is essential. Several growth factors are involved in this process,
such as the vascular endothelial growth factor (VEGF) and nerve growth factor (NGF). The angiogenesis process in
the normal ovary is a tightly controlled process that occurs in each ovarian cycle. Also, angiogenesis is critical for
ovarian cancer development and it is responsible for tumor spread, metastasis and its peritoneal dissemination.
Ovarian cancer is the fifth leading cause of cancer death in women and it is distinguished as the most lethal
gynecologic cancer. In recent years angiogenesis has been given considerable attention in order to identify targets
for developing effective anti-tumor therapies. Several molecules have been reported to promote angiogenesis,
such as platelet-derived growth factor (PDGF) and its receptors, the angiopoietin/Tie ligand/receptor system
and fibroblast growth factor (FGF). Primarily, VEGF has been identified to play key roles in driving angiogenesis.
The above-mentioned molecules are candidate drug targets. Used in combination with other treatments,
anti-angiogenic therapies have managed to reduce disease progression. The present review is focused in NGF
and its high affinity receptor tyrosine kinase A (TRKA). The expression of VEGF, proliferation and the angiogenesis
process in ovarian cancer is importantly induced by NGF, among other molecules.
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The ovary is one of the few adult organs that undergo
angiogenesis at regular intervals. In ovarian cancer,
disturbances in the angiogenic process are a key factor
in its development and subsequent progression [1].
Ovarian cancer is the most lethal gynecological cancer;
it remains with a low survival rate [2], and therefore,
understanding the mechanisms governing angiogenesis
is important in order to develop new strategies for its
treatment. Neurotrophins have been shown to be involved
in both normal ovarian and ovarian cancer angiogenesis
[3,4]; thus, targeting their signaling signifies a novel
therapeutic opportunity.* Correspondence: cromero@hcuch.cl
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unless otherwise stated.Neurotrophins and their receptors are involved in
mammalian ovarian development [5,6]. Besides, in the
normal human ovary, the neurotrophin nerve growth
factor (NGF) and its high affinity tyrosine kinase receptor
(TRKA) are expressed in granulosa cells [7], and through
the activation of TRKA, NGF induces an increase in the
vascular endothelial growth factor (VEGF) expression [8].
In human epithelial ovarian cancer (EOC) cells, NGF and
TRKA are also expressed [8], and the active form of TRKA
has been associated with poor patient outcome [9]. This
review will focus on our research efforts regarding the
connection between NGF, TRKA and VEGF, and how
these molecules have a relevant role in ovarian cancer
progression. We will discuss how NGF and TRKA are
involved in angiogenesis, cell proliferation and progression
of EOC.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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That neurotrophin or neuropeptide family and particularly
NGF are critical for cell survival and differentiation in
both the central and peripheral nervous system [10,11]
and their important role for non-neuronal tissue
development [12,13] are known facts. Such functions
were suggested by studies that evidenced the presence
of high affinity neurotrophin receptors in a variety of
non-neuronal tissues, including the cardiovascular,
endocrine, immune and reproductive systems [14].
Although all the functions developed by neurotrophins
in the ovary have not been identified yet, to date it is
clear that neurotrophins represent the trophic support
for the sympathetic innervation of the organ and that
they play a significant role during ovarian development
periods that are key to the reproductive function: early
follicular development [5] and ovulation [6]. Neurotrophins
facilitate early follicular development during the two
sequential phases of such process, which are: differentiation
of primordial follicles towards primary follicles and growth
of the latter into secondary follicles [5]. Such stages are
apparently related to the ability of nerve growth factor
(NGF) to act on the proliferation of both granulosa cells as
well as theca cells [5], and to follicular stimulating hormone
(FSH) receptor synthesis in granulosa cells [15]. Upon the
first ovulation, NGF contributes to the ovulatory cascade by
increasing the release of E2 prostaglandins (PGE2) [6],
decreasing gap-junction communication and inducing
theca cell proliferation in pre-ovulatory follicles [16].
All the processes described above have been demon-
strated in rodents. However, there is evidence showing
that neurotrophins and their receptors are also present
in the fetal human ovary [17] and that human granulosa
cells secrete another neuropeptide such as Brain-Derived
Neurotrophic Factor (BDNF) that might be participating
in oocyte maturation regulation [18]. Results obtained by
our group have shown that in the normal human ovary,
NGF and its high affinity TRKA receptor are mainly
expressed in granulosa cells of antral and preantral
follicles, as well as in theca cells of antral follicles. In
addition to such findings, we also observed that NGF
increases both the expression of FSH receptors, as well as
estradiol secretion by cultured human granulosa cells [7].
The expression of NGF and its receptor on human
granulosa cells of preantral and antral follicles [7]
matches the expression of VEGF [19]. The latter suggests
that at least some ovarian cells are prepared to provide
the paracrine stimulus required for new blood vessel
growth. During reproductive life, VEGF participates in
the cyclic growth of ovarian follicles as well as in the
development and maintenance of the corpus luteum.
VEGF expression and secretion are induced via the
activation of both FSH as well as luteinizing hormone
(LH) receptors. VEGF expression and productionwithin the ovary are critical to the normal reproduct-
ive function. Angiogenesis defects may contribute to a
variety of disorders including anovulation, infertility,
miscarriage, ovarian hyperstimulation syndrome and
ovarian cancer [20].
Because TRKA receptor expression in the ovary takes
place before ovulation [6] similarly to what happens with
VEGF [20], it might be presumed that both factors could
be acting concomitantly in important processes of ovarian
function and possibly in angiogenic processes that
take place during the follicular and luteal phases of
the ovarian cycle. Additionally, NGF [7], as well as
VEGF [20] is also reputed to be involved in certain
ovarian pathologies such as polycystic ovary.
When ovaries are autotransplanted to an ectopic site
in the rat, they swiftly recover functionality [21].
After 48 hours of ovary transplantation, they exhibit a
massive revascularization together with an increased
VEGF expression through a gonadotropin-related process
[22]; four days after transplantation they recover the ability
of performing a negative feedback on the hypothalamus-
pituitary axis [21].
Therefore, NGF alone or in combination with other
biologically active endogenous molecules, is able to exert
its action on endothelial cells and more probably on the
angiogenic activity [23]. It has also been suggested that
NGF stimulates VEGF production by peripheral sensory
neurons [23].
An increase in blood vessel density was observed
during the neovascularization process of the superior
cervical ganglion in newborn rats, when such animals
were treated with NGF. This effect is directly correlated
with an increased VEGF expression [24]. Such results
suggest that angiogenesis may be indirectly regulated
through NGF.
For such reason, knowing that human granulosa cells
express NGF and their high affinity receptor (TRKA), we
were interested in studying whether NGF was able to
regulate VEGF expression in cultures of such cells. Our
findings showed that in fact, NGF increases VEGF
expression in an autocrine fashion, by activating TRKA
receptor and through the subsequent activation of the
MAPK – ERK and PI3K and AKT signaling cascade [25].
The results obtained by our work group suggest that
in the adult human ovary NGF might be involved in
normal ovarian angiogenesis, through VEGF expression
and FSH receptor expression and also through estradiol
secretion prior to ovulation [7,25].
Ovarian cancer
Ovarian cancer is detected in late stages because it is
a silent pathological condition, with poor therapeutic
response and thus with a high mortality rate. Survival
rates do not exceed 31% of patients diagnosed with
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still unclear. Many mechanisms have been proposed
to explain ovarian cancer etiology. The Fathalla Theory
suggests that repeated ovulations represent a trauma to
the ovarian epithelium that renders such cells more
susceptible to malignant transformation [26]. Classically,
EOC has been described as originating from the
epithelium (OSE). The OSE is a single layer of modified
mesothelial cells that overlays the ovarian surface, and
is separated from ovarian stoma by the basal lamina.
Inclusion cysts (present within the ovarian stroma and
lined by the OSE cells) and ovarian surface invaginations
(lined by OSE cells) have been described as preferred
sites for neoplastic transformation [27]. This might be
explained by the fact that the ovary undergoes an
injury with each ovulation and thus, by virtue of local
factors, the epithelium begins uncontrolled proliferation
[28]. The latter is supported by evidences demonstrating
that EOC originates through the clonal expansion of one
single transformed stem cell [29]. However, recent studies
have suggested that in some cases, ovarian cancer might
originate from extraovarian epithelial lesions that settle on
the ovary and originate neoplasia [30]. Nevertheless, there
are no conclusive evidences demonstrating or supporting
such theory.
The series of events involved in the genesis, progression
and metastasis of EOC has not been yet established.
Evidence suggests that tumor progression of EOC occurs
slowly from benign or borderline tumors, or may develop
rapidly de novo from the OSE or inclusion cysts [29]. The
majorities of the malignant ovarian tumors are epithelial
(80%) and are highly angiogenic [27]. Angiogenesis is
a prerequisite for solid tumor growth after a short
avascular phase [31]; it involves capillary endothelial cell
proliferation [32] as well as migration [33]. Endothelial
cells in human tumors have a proliferation rate that is 50
or 200 fold higher than endothelial cells in normal adult
endothelial tissue [32].
The angiogenic process has a theoretical significance
in the context of ovarian cancer for two reasons. First,
the angiogenesis process occurs in a very controlled
fashion as part of the normal ovarian function, during
ovulation [20]. The latter suggests that at least some
ovarian cells are ready to provide the paracrine stimulus
required for the growth of new blood vessels, and
that, upon transformation, such ability is present early
during tumor development. Second, the large size that
characterizes ovarian tumors requires an angiogenesis
process for tumor sustenance [31].
VEGF is an angiogenic factor and potent mitogen for
the vascular endothelium and one of the most important
factors in ovarian angiogenesis [34]. Besides VEGF,
other molecules have been identified to play important
roles in promoting and maintaining angiogenesis duringthe oncogenic process. Such molecules include the
platelet-derived growth factor (PDGF) and its receptors,
the angiopoietin/Tie ligand/receptor system and the
fibroblast growth factor (FGF) [35]. PDGF leads to
upregulation of angiogenic events and to tumor
growth through the activation of its receptor, PDGFR.
It acts together with VEGF to induce vessel formation
and to stabilize the newly formed vessels. PDGF has
been found to increase in human ovarian cancer
tumor cells compared to normal ovarian epithelium
[35]. Angiopoietin, on the other hand, has two isoforms,
Ang1 and Ang2, both of which can interact with the Tie 2
receptor to induce new vessel production. In cancer, Ang2
has also been linked to metastasis [36]. Finally, FGF is
another molecule that plays a role in ovarian carcinogenesis.
It can induce tumor cell proliferation and it plays a role
in promoting angiogenesis in collaboration with VEGF. It
may also be secreted into malignant ascites promoting
both angiogenesis and cancer progression. Its receptor,
FGFR, is able to interact with adhesion molecules,
promoting metastasis [37]. Importantly, both PDGF
and FGF levels can be correlated with prognosis [35].
Currently, ovarian cancer treatment consists on the
surgical removal of the affected ovary or even a bilateral
oophorectomy, followed by chemotherapy. Most patients
respond to this line of treatment, however, the majority
of patients recur and the tumor develops drug resistance
[38]. In this context, given the low overall survival for
ovarian cancer, there is a great need for new therapeutic
approaches that are able to give more durable responses.
Angiogenesis appears as one of the main focuses for
future drug development. Molecular-targeted therapy, in
combination with cytotoxic treatment, may prove to be
a good strategy to improve ovarian cancer prognosis.
Up to the present time, there are no FDA-approved
anti-angiogenic drugs used in ovarian cancer treatment,
however, several clinical trials against the VEGF, Ang, FGF
and PDGF pathways have managed to reduce disease
progression [39].
NGF and TRKA in EOC
In addition to the importance of angiogenesis in tumor
processes, cancerous cells are characterized by a lack of
cell growth regulation control. This occurs in part
through signaling generated from a variety of growth
factor receptors, such as tyrosine kinase receptors [40,41].
In many cell types, overexpression of neurotrophin
receptors or changes in the activity of intracellular
signal transduction cascades are involved in malignant
transformation [40].
Some authors suggest that the interaction between
NGF and its specific receptor TRKA might be involved
in the growth of some non-neuronal cancers. Likewise,
an overexpression of neurotrophin receptor has been
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thyroid [40,41], lung [42], esophagus [43], prostate [44],
breast [45] and also in ovarian cancer [46] where expression
of TRKA receptors was detected in 82% of solid epithelial
tumors [32]. Neurotrophin receptor expression might have
a more than prognostic biological relevance in ovarian
carcinoma [46]; however, the few studies regarding
the participation of neurotrophins and their receptors
in such cancer do not enable reaching a valid conclusion.
For such reason it was important to assess cell proliferation
in EOC and some molecules involved in NGF- mediated
TRKA activation signaling pathway. Such study re-
vealed an increase in p-AKT protein levels, in BCL2/BAX
ratio, c-myc and Ki67. In turn, levels of FOXL2, a tran-
scription factor involved in apoptosis, were decreased [47].
In addition, a microarray study was performed to
evaluate changes in some genes involved in the previously
mentioned signaling pathway in EOC explants, and toFigure 1 Signaling pathways of TRKA activation by NGF. The NGF-dep
survival, differentiation and angiogenesis in EOC.compare them with a normal human ovarian epithelial
surface cell line (HOSE). Such results evidenced an
important increase of TRKA gene among EOC as
compared to HOSE cells and also an increase in
MAPK1, PI3K, and AKT2, without changes in FOXL2
gene [4] (Figure 1).
Relationship between NGF, TRKA and VEGF in EOC
angiogenesis
Autocrine and paracrine production of VEGF is the
critical component of angiogenesis both in normal as
well as in pathological tissues.
As a product of alternative splicing of the gene, five
VEGF isoforms have been detected in mammals:
VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206
transcripts [47]. Transcripts coding for VEGF121, VEGF165
and VEGF189 are detected in the majority of cells express-
ing the VEGF gene, in which the main molecular species isendent activation pathway of TRKA is involved in cellular proliferation,
Figure 2 NGF and its TRKA receptor are involved in the progression of EOC. In EOC, NGF and its TRKA receptor are expressed in both
epithelial and endothelial cells and are involved in important process such as angiogenesis during the tumor progression.
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has only been described in human fetal liver [20,48].
VEGF189 and VEGF206 have been observed to bind to
heparin and to be almost completely sequestered in
the extracellular matrix. On the other hand, an important
fraction of VEGF121, VEGF145 and VEGF165 are secreted:
however, an important fraction of VEGF165 remains bound
to the cell surface and the extracellular matrix [49].
The predominant expression of VEGF121 and VEGF165
isoforms mRNA has been demonstrated in normal ovary
and EOC [49,50]. The mRNA for such isoforms are
overexpressed in most human tumors, including ovariantumors [50]. When correlating VEGF expression with
tumor characteristics, increased levels of VEGF165 have
been found in all ovarian carcinoma stages, regardless of
their histological type [50]. A study carried out on ovarian
carcinoma cell lines and ovarian tumors in different
stages demonstrated a higher predominant expression
of VEGF121 and VEGF165; however, the VEGF189
isoform was found in two of six of the studied cell
lines, and in some cases of ovarian cancer in more
advanced stages [51].
The results obtained by our group show that mRNA
levels of the three VEGF isoforms (VEGF121, VEGF165
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tissue as well as in EOC [8]. When comparing such
isoform transcripts expression in both tissues there is a
significant increase of VEGF165 and VEGF189 transcripts
in EOC [8]. Moreover, when studying NGF – induced
VEGF expression in cultured EOC explants; we found that
NGF generates a significant increase of both mRNA
as well as of the protein of the three above-mentioned
isoforms [8]. Such effect was inhibited by NGF
immuno-blockade and by a tyrosine kinase inhibitor
(K252a), thus indicating that VEGF expression regulation
by NGF in EOC is specific and mediated by the activation
of its TRKA receptor [8].
There is practically no information regarding TRKA
receptor expression in normal OSE cells. However, there
are two studies [12,52] conducted with a small number
of samples, where expression of such receptor in that
epithelium could not be found. By virtue of detecting
NGF and TRKA with immunohistochemistry in a larger
number of normal ovary samples, our group found a mild
NGF detection and even lower TRKA immunodetection
in OSE in 10% of the cases studied [8]. Additionally we
have also found NGF and TRKA expression in EOC
tissues, similar to literature reports [46,52]. Interestingly,
upon determination of mRNA and protein levels for
NGF, TRKA and VEGF in normal ovary, benign tumors,
borderline tumors, well differentiated EOC, moderately
differentiated ovarian cancer and poorly differentiated
ovarian cancer specimens, we found a sustained increase
of NGF, TRKA and VEGF both transcripts as well as
proteins in the epithelia of such tissues, evidencing a
correlation with EOC progression. However, the most
important changes were found for the phosphorylated
TRKA receptor (p-TRKA), proving that such receptor
is chiefly activated as tissue differentiation is lost and
thus, when tissue is more aggressive [53]. The latter
suggests that p-TRKA might be a marker for poor progno-
sis. Furthermore, NGF, total TRKA total and p-TRKA
immunodetection was positive in endothelial cells of the
same tissues and with similar increases to those found in
the epithelia of such tissues [53]. For such reason, we
decided to evaluate the effect of NGF- and VEGF-
conditioned media secreted by EOC explants and by
an EOC cell line (A2780) on cell proliferation, migration
and differentiation in a human endothelial cell line
(Eahy926). A significant increase in endothelial cell
proliferation, migration and differentiation (vasculogenesis)
was observed. Such effect decreased when using a
tyrosine kinase receptor inhibitor (A252a) and when
immune-blocking NGF with an antibody [53].
Conclusion
Neurotrophins were first discovered in the brain, and
their signaling pathways have mostly been studied inneurons. However, NGF has several functions outside
the nervous system, including important roles in the
development and normal functioning of the ovary. Besides,
the TRKA signaling pathway due to NGF stimulation
has been linked to cancer before. A deregulation in
NGF signaling has been shown to promote prolifera-
tion, migration, angiogenesis and metastasis in differ-
ent cancers, including breast cancer, melanoma and
pancreatic cancer.
The data summarized above demonstrates that
when NGF activates its high affinity receptor TRKA
in human granulosa cells of normal ovary and in epithelial
cells from EOC, it acts as an indirect angiogenic
factor by increasing VEGF expression and also as a direct
angiogenic factor by activating TRKA in endothelial
cells, therefore increasing angiogenesis in EOC (Figure 2).
Additionally, the above-described results enable us to
conjecture that both NGF as well as TRKA receptor
expression in normal OSE might be early events in
EOC tumorigenesis and angiogenesis, giving us a better
understanding in the function of neurotrophins in human
carcinoma.
In the future, studies should focus on NGF levels on
ovarian cancer patients, and its correlation with prognosis.
Also, TRKA, the active TRKA form and NGF levels should
be contrasted with survival after the current available
therapies. Targeting the NGF-TRKA pathway could
offer new approaches to the therapy of ovarian cancer,
and it could be complementary to therapies that target
VEGF. Also, further study is needed to elucidate if the
relationship between angiogenesis, NGF, TRKA and VEGF
is also present in other types of cancer.
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